The estimated Net Worth of Mary Tedd Allen is at least $1.2 Million dollars as of 1 July 2019. Dr Allen owns over 64,333 units of Nanostring Technologies Inc stock worth over $9,979 and over the last 11 years he sold NSTG stock worth over $1,189,352.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Dr Allen NSTG stock SEC Form 4 insiders trading
Dr has made over 6 trades of the Nanostring Technologies Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 64,333 units of NSTG stock worth $1,014,531 on 1 July 2019.
The largest trade he's ever made was exercising 64,333 units of Nanostring Technologies Inc stock on 1 July 2019 worth over $1,014,531. On average, Dr trades about 9,096 units every 15 days since 2013. As of 1 July 2019 he still owns at least 94,766 units of Nanostring Technologies Inc stock.
You can see the complete history of Dr Allen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Mary Tedd Allen biography
Dr. Mary Tedd Allen is the Sr. VP of Strategic Initiatives at Nanostring Technologies Inc.
How old is Dr Allen?
Dr Allen is 58, he's been the Sr. VP of Strategic Initiatives of Nanostring Technologies Inc since . There are 9 older and 8 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.
What's Dr Allen's mailing address?
Mary's mailing address filed with the SEC is 530 Fairview Ave N, Seattle, WA 98109, USA.
Insiders trading at Nanostring Technologies Inc
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus..., and Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
What does Nanostring Technologies Inc do?
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
What does Nanostring Technologies Inc's logo look like?
Complete history of Dr Allen stock trades at Nanostring Technologies Inc
Nanostring Technologies Inc executives and stock owners
Nanostring Technologies Inc executives and other stock owners filed with the SEC include:
-
R. Bradley Gray,
President, Chief Executive Officer, Director -
K. Thomas Bailey,
Chief Financial Officer -
Joseph Beechem,
Senior Vice President - Research and Development -
John Brown,
Senior Vice President - Sales and Marketing -
David Ghesquiere,
Senior Vice President - Corporate and Business Development -
R. Bradley Gray,
CEO, Pres & Director -
K. Thomas Bailey M.B.A.,
Chief Financial Officer -
Dr. Joseph M. Beechem,
Chief Scientific Officer and Sr. VP of R&D -
J. Chad Brown,
Sr. VP of Sales & Marketing -
David W. Ghesquiere,
Sr. VP of Corp. & Bus. Devel. -
William Young,
Independent Chairman of the Board -
Gregory Norden,
Independent Director -
Don Kania,
Independent Director -
Charles Waite,
Independent Director -
Elisha Finney,
Independent Director -
Kirk Malloy,
Independent Director -
Robert Hershberg,
Independent Director -
Elizabeth Schneider Ph.D.,
Sr. Global Marketing Mang. -
Dr. Philippa Webster Ph.D.,
Sr. Principal Scientist -
Dr. Mary Tedd Allen,
Sr. VP of Strategic Initiatives -
Kathryn Surace-Smith,
Sr. VP of HR & Legal Affairs and Corp. Sec. -
Douglas S. Farrell,
VP of Investor Relations & Corp. Communications -
Mark A. Winham,
Sr. VP of Operations -
Teresa M. Foy,
Director -
Nicholas Galakatos,
Director -
Lifesciences Ii, L.P.Clarus...,
-
Wayne Burns,
SVP, Operations & Admin -
James A Johnson,
Chief Financial Officer -
J. Chad Brown,
SVP, Sales & Marketing -
Mary Tedd Allen,
SVP, Operations -
Lifesciences Ii, L.P.Clarus...,
-
Barney Saunders,
SVP & GM, Life Sciences -
Venture Partners Vi Lpovp V...,
-
Fisher Jurvetson Fund Vii, ...,
-
Finny Kuruvilla,
Director -
Tina Susan Nova,
Director -
Bruce J. Seeley,
SVP & GM, Diagnostics -
J Wayne Cowens,
Chief Medical Officer -
Jennifer Scott Fonstad,
Director -
Bradford Crutchfield,
Director -
Janet George,
Director -
Dana E. Rollison,
Director -
John D. Gerace,
Chief Commercial Officer -
Jonathan Todd Garland,
Chief Commercial Officer